New drug combo tackles Hard-to-Treat cancers in early trial
NCT ID NCT05514444
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This early-stage study tested a new drug called MK-4464, given alone or with another cancer drug (pembrolizumab), in 64 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, how the body processes it, and to find the right dose. This is not a cure, but a step toward better controlling these hard-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC, locatie VUmc ( Site 0400)
Amsterdam, North Holland, 1081HV, Netherlands
-
Hadassah Medical Center-Oncology ( Site 0302)
Jerusalem, 9112001, Israel
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0401)
Amsterdam, North Holland, 1066CX, Netherlands
-
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201)
Toronto, Ontario, M5G 2M9, Canada
-
Rambam Health Care Campus-Oncology Division ( Site 0300)
Haifa, 3109601, Israel
-
The University of Louisville, James Graham Brown Cancer Center ( Site 0100)
Louisville, Kentucky, 40245, United States
Conditions
Explore the condition pages connected to this study.